Gülay Sezgin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gülay Sezgin has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Serhan Küpeli
ÇUKUROVA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ÇOCUK SAĞLIĞI VE HASTALIKLARI ANABİLİM DALI, ONKOLOJİ BİLİM DALI
17 shared publications - Ibrahim Bayram
ÇUKUROVA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ÇOCUK SAĞLIĞI VE HASTALIKLARI ANABİLİM DALI, ONKOLOJİ BİLİM DALI
11 shared publications - Ayşe Özkan
Department of Pediatric Hematology-Oncology, Faculty of Medicine, Çukurova University, Adana, Türkiye
9 shared publications - Atila Tanyeli
ÇUKUROVA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ÇOCUK SAĞLIĞI VE HASTALIKLARI ANABİLİM DALI, ONKOLOJİ BİLİM DALI
4 shared publications - Atila Tanyeli
Cukurova University Faculty of Medicine
3 shared publications Ayse Ozkan
3 shared publications
Latest Publications
- Open Access
- 30 June 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (2) , 506-518
Improved outcomes in children with acute lymphoblastic leukemia treated with modified BFM protocols: a single-center experience
Purpose: We compared the treatment protocols used for acute lymphoblastic leukemia (ALL) patients admitted to our clinic between January 1990 and September 2021. Materials and Methods: Patient files were retrospectively reviewed. Data collection was finalized in June 2022. Patients were divided into three groups based on treatment protocols. Group I (n=234) received BFM-85, -90, or -95 protocols between 1990 and January 2001. Group II (n=139) received a modified BFM-95 protocol (TRALL-2000) between January 2001 and March 2007. Group III (n=199) received a center-modified TRALL-2000 protocol starting in 2007. Results: Of the patients, 344 (60.1%) were boys and 228 (39.9%) were girls. The 10-year overall survival (OS) rates were 30%, 53%, and 73% for Groups I, II, and III, respectively. Event-free survival (EFS) rates were 27%, 40%, and 64%. In Group III, the 10-year OS was 92% for the standard-risk group (SRG), 71% for the medium-risk group (MRG), and 59% for the high-risk group (HRG); the corresponding EFS rates were 72%, 68%, and 49%. Among Group III patients, the 10-year OS was 64% for girls and 78% for boys. The OS for B-cell ALL was 71%, and for T-cell ALL, 78%. Conclusion: OS and EFS rates in Group III were significantly higher than in earlier groups. Contrary to existing literature, T-cell ALL patients and male patients in Group III had superior outcomes compared to B-cell ALL patients and female patients.
- 30 June 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (2) , 506-518
Open AccessImproved outcomes in children with acute lymphoblastic leukemia treated with modified BFM protocols: a single-center experience
Purpose: We compared the treatment protocols used for acute lymphoblastic leukemia (ALL) patients admitted to our clinic between January 1990 and September 2021. Materials and Methods: Patient files were retrospectively reviewed. Data collection was finalized in June 2022. Patients were divided into three groups based on treatment protocols. Group I (n=234) received BFM-85, -90, or -95 protocols between 1990 and January 2001. Group II (n=139) received a modified BFM-95 protocol (TRALL-2000) between January 2001 and March 2007. Group III (n=199) received a center-modified TRALL-2000 protocol starting in 2007. Results: Of the patients, 344 (60.1%) were boys and 228 (39.9%) were girls. The 10-year overall survival (OS) rates were 30%, 53%, and 73% for Groups I, II, and III, respectively. Event-free survival (EFS) rates were 27%, 40%, and 64%. In Group III, the 10-year OS was 92% for the standard-risk group (SRG), 71% for the medium-risk group (MRG), and 59% for the high-risk group (HRG); the corresponding EFS rates were 72%, 68%, and 49%. Among Group III patients, the 10-year OS was 64% for girls and 78% for boys. The OS for B-cell ALL was 71%, and for T-cell ALL, 78%. Conclusion: OS and EFS rates in Group III were significantly higher than in earlier groups. Contrary to existing literature, T-cell ALL patients and male patients in Group III had superior outcomes compared to B-cell ALL patients and female patients.
- Open Access
- 31 March 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (1) , 83-89
Assessment of respiratory functions in pediatric oncology patients receiving bleomycin treatment
Purpose: Bleomycin is a chemotherapeutic agent that causes lung toxicity. Bleomycin is mostly used in the treatment of germ cell tumors (GCT) and Hodgkin Lymphoma (HL) in childhood cancers. In this study, we aimed to detect bleomycin toxicity to the lung in the early period. Materials and Methods: Pulmonary functions of patients aged 5 years and older who were admitted to the Division of Pediatric Oncology with GCT and HL between 2012 and 2022, who received bleomycin treatment and were in remission for at least 6 months were evaluated. The evaluation of respiratory functions was based on history, physical examination, posteroanterior chest radiography (chest X-ray) and pulmonary function test (PFT). Results: The number of patients with GCT who entered follow-up and lived were 59, those with HL were 89. The number of patients who received bleomycin treatment, were in remission for at least 6 months, could be reached and underwent PFT were 46 for HL and 12 for GCT. There were 21 patients with PFT abnormalities. Of these patients, 3 were diagnosed with GCT and 18 were diagnosed with HL. The type of PFT abnormality in the majority of patients was restrictive disorder. Conclusion: The absence of respiratory symptoms in 90% of patients with PFT abnormalities shows the importance of PFT in asymptomatic patients. Patients who have received bleomycin as part of treatment should also be followed-up for late pulmonary toxicity.
- 31 March 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (1) , 83-89
Open AccessAssessment of respiratory functions in pediatric oncology patients receiving bleomycin treatment
Purpose: Bleomycin is a chemotherapeutic agent that causes lung toxicity. Bleomycin is mostly used in the treatment of germ cell tumors (GCT) and Hodgkin Lymphoma (HL) in childhood cancers. In this study, we aimed to detect bleomycin toxicity to the lung in the early period. Materials and Methods: Pulmonary functions of patients aged 5 years and older who were admitted to the Division of Pediatric Oncology with GCT and HL between 2012 and 2022, who received bleomycin treatment and were in remission for at least 6 months were evaluated. The evaluation of respiratory functions was based on history, physical examination, posteroanterior chest radiography (chest X-ray) and pulmonary function test (PFT). Results: The number of patients with GCT who entered follow-up and lived were 59, those with HL were 89. The number of patients who received bleomycin treatment, were in remission for at least 6 months, could be reached and underwent PFT were 46 for HL and 12 for GCT. There were 21 patients with PFT abnormalities. Of these patients, 3 were diagnosed with GCT and 18 were diagnosed with HL. The type of PFT abnormality in the majority of patients was restrictive disorder. Conclusion: The absence of respiratory symptoms in 90% of patients with PFT abnormalities shows the importance of PFT in asymptomatic patients. Patients who have received bleomycin as part of treatment should also be followed-up for late pulmonary toxicity.
- 24 April 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (3) , e14758
COVID‐19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group
Background: Data on the risk factors and outcomes for pediatric patients with SARS‐CoV‐2 infection (COVID‐19) following hematopoietic stem cell transplantation (HSCT) are limited.Objectives: The study aimed to analyze the clinical signs, risk factors, and outcomes for ICU admission and mortality in a large pediatric cohort who underwent allogeneic HSCT prior to COVID‐19 infection.Method: In this nationwide study, we retrospectively reviewed the data of 184 pediatric HSCT recipients who had COVID‐19 between March 2020 and August 2022.Results: The median time from HSCT to COVID‐19 infection was 209.0 days (IQR, 111.7–340.8; range, 0–3845 days). The most common clinical manifestation was fever (58.7%). While most patients (78.8%) had asymptomatic/mild disease, the disease severity was moderate in 9.2% and severe and critical in 4.4% and 7.6%, respectively. The overall mortality was 10.9% (n: 20). Deaths were attributable to COVID‐19 in nine (4.9%) patients. Multivariate analysis revealed that lower respiratory tract disease (LRTD) (OR, 23.20, p: .001) and lymphopenia at diagnosis (OR, 5.21, p: .006) were risk factors for ICU admission and that HSCT from a mismatched donor (OR, 54.04, p: .028), multisystem inflammatory syndrome in children (MIS‐C) (OR, 31.07, p: .003), and LRTD (OR, 10.11, p: .035) were associated with a higher risk for COVID‐19‐related mortality.Conclusion: While COVID‐19 is mostly asymptomatic or mild in pediatric transplant recipients, it can cause ICU admission in those with LRTD or lymphopenia at diagnosis and may be more fatal in those who are transplanted from a mismatched donor and those who develop MIS‐C or LRTD.
- 24 April 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (3) , e14758
COVID‐19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group
Background: Data on the risk factors and outcomes for pediatric patients with SARS‐CoV‐2 infection (COVID‐19) following hematopoietic stem cell transplantation (HSCT) are limited.Objectives: The study aimed to analyze the clinical signs, risk factors, and outcomes for ICU admission and mortality in a large pediatric cohort who underwent allogeneic HSCT prior to COVID‐19 infection.Method: In this nationwide study, we retrospectively reviewed the data of 184 pediatric HSCT recipients who had COVID‐19 between March 2020 and August 2022.Results: The median time from HSCT to COVID‐19 infection was 209.0 days (IQR, 111.7–340.8; range, 0–3845 days). The most common clinical manifestation was fever (58.7%). While most patients (78.8%) had asymptomatic/mild disease, the disease severity was moderate in 9.2% and severe and critical in 4.4% and 7.6%, respectively. The overall mortality was 10.9% (n: 20). Deaths were attributable to COVID‐19 in nine (4.9%) patients. Multivariate analysis revealed that lower respiratory tract disease (LRTD) (OR, 23.20, p: .001) and lymphopenia at diagnosis (OR, 5.21, p: .006) were risk factors for ICU admission and that HSCT from a mismatched donor (OR, 54.04, p: .028), multisystem inflammatory syndrome in children (MIS‐C) (OR, 31.07, p: .003), and LRTD (OR, 10.11, p: .035) were associated with a higher risk for COVID‐19‐related mortality.Conclusion: While COVID‐19 is mostly asymptomatic or mild in pediatric transplant recipients, it can cause ICU admission in those with LRTD or lymphopenia at diagnosis and may be more fatal in those who are transplanted from a mismatched donor and those who develop MIS‐C or LRTD.
- 13 March 2024
- Published by Springer Nature in Child's Nervous System
- Vol. 40 (6) , 1671-1680
Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma
Purpose Pediatric diffuse intrinsic pontine glioma (DIPG) is a fatal disease associated with a median survival of < 1 year despite aggressive treatments. This retrospective study analyzed the treatment outcomes of patients aged < 18 years who were diagnosed with DIPG between 2012 and 2022 and who received different chemotherapy regimens. Methods After radiotherapy, patients with DIPG received nimotuzumab-vinorelbine combination or temozolomide-containing therapy. When nimotuzumab was unavailable, it was replaced by vincristine, etoposide, and carboplatin/cyclophosphamide (VECC). Temozolomide was administered as a single agent or a part of the combination chemotherapy comprising temozolomide, irinotecan, and bevacizumab. Furthermore, 1- and 3-year overall survival (OS), progression-free survival (PFS), and median OS and PFS were analyzed. Results The median age of 40 patients with DIPG was 97 ± 46.93 (23–213) months; the median follow-up time was 12 months. One and 3-year OS were 35.0% and 7.5%, respectively. Median OS was 12 months in all patients (n = 40), and it was 16, 10, and 11 months in those who received first-line nimotuzumab-vinorelbine combination (n = 13), temozolomide-based (n = 14), and VECC (n = 6) chemotherapy regimens, respectively (p = 0.360). One patient who received gefitinib survived for 16 months. Conversely, patients who never received radiotherapy and any antineoplastic medicamentous therapy (n = 6) had a median OS of 4 months. Conclusion Nimotuzumab-vinorelbine combination therapy prolonged OS by 6 months compared with temozolomide-containing chemotherapy, although the difference was not statistically significant.
- 13 March 2024
- Published by Springer Nature in Child's Nervous System
- Vol. 40 (6) , 1671-1680
Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma
Purpose Pediatric diffuse intrinsic pontine glioma (DIPG) is a fatal disease associated with a median survival of < 1 year despite aggressive treatments. This retrospective study analyzed the treatment outcomes of patients aged < 18 years who were diagnosed with DIPG between 2012 and 2022 and who received different chemotherapy regimens. Methods After radiotherapy, patients with DIPG received nimotuzumab-vinorelbine combination or temozolomide-containing therapy. When nimotuzumab was unavailable, it was replaced by vincristine, etoposide, and carboplatin/cyclophosphamide (VECC). Temozolomide was administered as a single agent or a part of the combination chemotherapy comprising temozolomide, irinotecan, and bevacizumab. Furthermore, 1- and 3-year overall survival (OS), progression-free survival (PFS), and median OS and PFS were analyzed. Results The median age of 40 patients with DIPG was 97 ± 46.93 (23–213) months; the median follow-up time was 12 months. One and 3-year OS were 35.0% and 7.5%, respectively. Median OS was 12 months in all patients (n = 40), and it was 16, 10, and 11 months in those who received first-line nimotuzumab-vinorelbine combination (n = 13), temozolomide-based (n = 14), and VECC (n = 6) chemotherapy regimens, respectively (p = 0.360). One patient who received gefitinib survived for 16 months. Conversely, patients who never received radiotherapy and any antineoplastic medicamentous therapy (n = 6) had a median OS of 4 months. Conclusion Nimotuzumab-vinorelbine combination therapy prolonged OS by 6 months compared with temozolomide-containing chemotherapy, although the difference was not statistically significant.
- 26 January 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14691
Improvement of survival after hematopoietic stem cell transplantation and trends at a pediatric transplantation center; a three‐decade journey
Background: Advances in stem cell transplantation have resulted in improved outcomes.Methods: This is a retrospective study aimed to analyze changes in patient profile, transplantation, graft characteristics, and outcome among 241 pediatric patients who received stem cell transplantation in a single center between 1993 and 2019.Results: In the 2010–2019, compared with the 1993–2009 period, a significantly higher 5‐year overall survival (60% vs. 44%, p = .022) and an event‐free survival (53% vs. 34%, p = .025) were observed. Cumulative incidence of deaths due to relapse or progression between the 1993–2009 and 2010–2019 periods were 33% and 26% respectively (p = .66). Cumulative incidence of non‐relapse mortality was significantly higher during the 1993–2009 period compared with the 2010–2019 period for malignant diseases (57.7% vs. 28.3%, p = .007). The overall survival from acute graft‐versus‐host disease between 1993 and 2009 was 11% versus 46% between 2010 and 2019 (p = .0001). The overall survival from infection in both eras did not show any difference (p = .41).Conclusions: Development in transplantation technology has led to a decrease in non‐relapse mortality and better control of graft‐versus‐host disease. However, relapse and infection remained as major causes of death. Studies evaluating institutional trends in patients undergoing HSCT and analyzing their mortality profile, can improve the management of patients, leading to a reduction in transplant‐related problems.
- 26 January 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14691
Improvement of survival after hematopoietic stem cell transplantation and trends at a pediatric transplantation center; a three‐decade journey
Background: Advances in stem cell transplantation have resulted in improved outcomes.Methods: This is a retrospective study aimed to analyze changes in patient profile, transplantation, graft characteristics, and outcome among 241 pediatric patients who received stem cell transplantation in a single center between 1993 and 2019.Results: In the 2010–2019, compared with the 1993–2009 period, a significantly higher 5‐year overall survival (60% vs. 44%, p = .022) and an event‐free survival (53% vs. 34%, p = .025) were observed. Cumulative incidence of deaths due to relapse or progression between the 1993–2009 and 2010–2019 periods were 33% and 26% respectively (p = .66). Cumulative incidence of non‐relapse mortality was significantly higher during the 1993–2009 period compared with the 2010–2019 period for malignant diseases (57.7% vs. 28.3%, p = .007). The overall survival from acute graft‐versus‐host disease between 1993 and 2009 was 11% versus 46% between 2010 and 2019 (p = .0001). The overall survival from infection in both eras did not show any difference (p = .41).Conclusions: Development in transplantation technology has led to a decrease in non‐relapse mortality and better control of graft‐versus‐host disease. However, relapse and infection remained as major causes of death. Studies evaluating institutional trends in patients undergoing HSCT and analyzing their mortality profile, can improve the management of patients, leading to a reduction in transplant‐related problems.
- Open Access
- 30 October 2023
- Published by Medknow in Nigerian Journal of Clinical Practice
- Vol. 26 (10) , 1563-1567
Quality of Life in Parents of Turkish and Syrian Pediatric Bone Marrow Transplant and Oncology Patients
Background: The success of the treatment depends on the well-being of the parents in pediatric cancer patients. In addition, migrants need to deal with the consequences of war. Aim: Our purpose was to compare the HRQoL of parents of Syrian and Turkish children followed in our bone marrow transplant and oncology units. Materials and Methods: One hundred SF 36 questionnaires, fifty from each group were collected between October 2019 and March 2020 in this cross-sectional study. Demographic characteristics of the patients (sex, age, cancer type, presence of relapse, duration of follow-up) and education level of parents were recorded. Analyses were performed using IBM SPSS Statistics version 20.0. Results: Turkish parents reported better results in physical functioning, emotional well-being, physical pain, general health, and physical health composite score (P < 0.05). There were more fathers in the Syrian group and education status was significant between the two groups (P = 0.01, P = 0.001, respectively). There was no correlation between QoL and education levels in the Turkish group. In Syrian parents, pain score was high in middle school graduates (P = 0.043). In the presence of relapse, although the physical function score decreased, the physical role function score increased in Turkish parents (P = 0.0035, P = 0.005, respectively). Syrian parents’ emotional role function and energy/fatigue score were both increased when children had relapses (P = 0.027for both). Conclusion: Migration is a complex issue. Turkish parents were better in physical functioning, emotional well-being, physical pain, general health, and physical health composite score. Screening for parental burden, assisting them to find appropriate support services is essential in improving the health and QoL of both our patients and their parents.
- 30 October 2023
- Published by Medknow in Nigerian Journal of Clinical Practice
- Vol. 26 (10) , 1563-1567
Open AccessQuality of Life in Parents of Turkish and Syrian Pediatric Bone Marrow Transplant and Oncology Patients
Background: The success of the treatment depends on the well-being of the parents in pediatric cancer patients. In addition, migrants need to deal with the consequences of war. Aim: Our purpose was to compare the HRQoL of parents of Syrian and Turkish children followed in our bone marrow transplant and oncology units. Materials and Methods: One hundred SF 36 questionnaires, fifty from each group were collected between October 2019 and March 2020 in this cross-sectional study. Demographic characteristics of the patients (sex, age, cancer type, presence of relapse, duration of follow-up) and education level of parents were recorded. Analyses were performed using IBM SPSS Statistics version 20.0. Results: Turkish parents reported better results in physical functioning, emotional well-being, physical pain, general health, and physical health composite score (P < 0.05). There were more fathers in the Syrian group and education status was significant between the two groups (P = 0.01, P = 0.001, respectively). There was no correlation between QoL and education levels in the Turkish group. In Syrian parents, pain score was high in middle school graduates (P = 0.043). In the presence of relapse, although the physical function score decreased, the physical role function score increased in Turkish parents (P = 0.0035, P = 0.005, respectively). Syrian parents’ emotional role function and energy/fatigue score were both increased when children had relapses (P = 0.027for both). Conclusion: Migration is a complex issue. Turkish parents were better in physical functioning, emotional well-being, physical pain, general health, and physical health composite score. Screening for parental burden, assisting them to find appropriate support services is essential in improving the health and QoL of both our patients and their parents.
- Open Access
- 30 June 2023
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 48 (2) , 377-384
DNA polymerase delta (POLD1 and POLD2) gene expression in pediatric acute lymphoblastic leukemia patients and its relationship with prognosis
Purpose: This study aimed to investigate the status of DNA polymerase delta (POLD1 and POLD2) gene expression at the time of diagnosis in pediatric acute lymphoblastic leukemia (ALL) patients, compared with the normal population, and its relationship with prognosis and other clinical findings. Materials and Methods: Seventy-three patients diagnosed with ALL between January 2008 and November 2015 and 29 healthy control subjects were included in the study. Gene expression profiling of peripheral blood samples was performed using Real-time PCR. Results: The mean value of POLD1 gene expression was found to be significantly higher in ALL patients at the time of diagnosis than the control group (376.5± 685.8 and 17.9± 19.8, respectively), but there was no difference in POLD2 gene expression (511.5± 898.1 and 125.4± 132.7, respectively). POLD1 and POLD2 gene expressions were found to be low in patients with relapse and exitus, but the results were not statistically significant. Patients with low levels of POLD1 expression had lower survival rates in the 5th year than those with high levels of expression (54% and 68%, respectively), and similarly, patients with low levels of POLD2 expression had lower survival rates in the 5th year compared to those with high levels of expression (58% and 68%, respectively). Conclusion: Lower POLD1 and POLD2 expressions at the time of diagnosis in ALL patients may adversely affects the prognosis.
- 30 June 2023
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 48 (2) , 377-384
Open AccessDNA polymerase delta (POLD1 and POLD2) gene expression in pediatric acute lymphoblastic leukemia patients and its relationship with prognosis
Purpose: This study aimed to investigate the status of DNA polymerase delta (POLD1 and POLD2) gene expression at the time of diagnosis in pediatric acute lymphoblastic leukemia (ALL) patients, compared with the normal population, and its relationship with prognosis and other clinical findings. Materials and Methods: Seventy-three patients diagnosed with ALL between January 2008 and November 2015 and 29 healthy control subjects were included in the study. Gene expression profiling of peripheral blood samples was performed using Real-time PCR. Results: The mean value of POLD1 gene expression was found to be significantly higher in ALL patients at the time of diagnosis than the control group (376.5± 685.8 and 17.9± 19.8, respectively), but there was no difference in POLD2 gene expression (511.5± 898.1 and 125.4± 132.7, respectively). POLD1 and POLD2 gene expressions were found to be low in patients with relapse and exitus, but the results were not statistically significant. Patients with low levels of POLD1 expression had lower survival rates in the 5th year than those with high levels of expression (54% and 68%, respectively), and similarly, patients with low levels of POLD2 expression had lower survival rates in the 5th year compared to those with high levels of expression (58% and 68%, respectively). Conclusion: Lower POLD1 and POLD2 expressions at the time of diagnosis in ALL patients may adversely affects the prognosis.
- Open Access
- 31 March 2023
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 48 (1) , 64-71
Expression of nuclear pore protein POM121 in childhood acute lymphoblastic leukemias and its relationship with prognosis
Purpose: We aimed to investigate the status of POM121 gene expression, which is one of the nuclear pore proteins in childhood acute lymphoblastic leukemias (ALL), compared with the normal population, and its relationship with prognosis and other clinical findings. Materials and Methods: Fifty-nine patients with ALL followed up and treated between January 2008 and November 2013, and 36 control subjects were included in the study. A real-time PCR method was used to detect POM121 gene expressions. Results: The mean value of POM121 expression was 3.75±2.91 in ALL patients and 3.32±3.76 in the control group. The 3 and 10 year overall survival (OS) was better in ALL with lower POM121 expression (77%, 70% versus 68%, 58%, respectively). Although the OS was better in B-ALL patients, with lower POM121 expression (84%, 75% versus 54%, 46%, respectively), in T-ALL, in contrast, the OS results were better in patients with a higher POM121 expression (90%, 90% versus 60%, 60%, respectively). Patients with a higher POM121 expression than the mean of the control group and who had relapse and central nervous system involvement had statistically significantly lower OS results in the 3rd and 10th years (16%, 0% versus 84%, 78%, respectively). Conclusion: High POM121 expression negatively affects the prognosis in patients with ALL. This is a study to show the relationship between POM121 expression and prognosis in childhood acute lymphoblastic leukemias, POM121 function will be clarified further with more comprehensive studies.
- 31 March 2023
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 48 (1) , 64-71
Open AccessExpression of nuclear pore protein POM121 in childhood acute lymphoblastic leukemias and its relationship with prognosis
Purpose: We aimed to investigate the status of POM121 gene expression, which is one of the nuclear pore proteins in childhood acute lymphoblastic leukemias (ALL), compared with the normal population, and its relationship with prognosis and other clinical findings. Materials and Methods: Fifty-nine patients with ALL followed up and treated between January 2008 and November 2013, and 36 control subjects were included in the study. A real-time PCR method was used to detect POM121 gene expressions. Results: The mean value of POM121 expression was 3.75±2.91 in ALL patients and 3.32±3.76 in the control group. The 3 and 10 year overall survival (OS) was better in ALL with lower POM121 expression (77%, 70% versus 68%, 58%, respectively). Although the OS was better in B-ALL patients, with lower POM121 expression (84%, 75% versus 54%, 46%, respectively), in T-ALL, in contrast, the OS results were better in patients with a higher POM121 expression (90%, 90% versus 60%, 60%, respectively). Patients with a higher POM121 expression than the mean of the control group and who had relapse and central nervous system involvement had statistically significantly lower OS results in the 3rd and 10th years (16%, 0% versus 84%, 78%, respectively). Conclusion: High POM121 expression negatively affects the prognosis in patients with ALL. This is a study to show the relationship between POM121 expression and prognosis in childhood acute lymphoblastic leukemias, POM121 function will be clarified further with more comprehensive studies.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15562
Pediatric posterior reversible encephalopathy syndrome: Age related clinico‐radiological profile and neurologic outcomes
Background: The aim of this study was to analyze the characteristics of pediatric posterior reversible encephalopathy syndrome (PRES) to determine clinical and radiologic differences between younger and older age groups, and to identify risk factors for development of any neurologic sequelae.Methods: The study cohort consisted of confirmed pediatric PRES patients in a tertiary care university hospital from January, 2015, to December, 2020. Demographic and clinical properties, radiological manifestations, and neurologic outcomes were noted. Children aged ≤6 years were compared with those older than 6 years and factors affecting neurologic outcomes were evaluated.Results: The most common underlying diseases were oncological (37%) and kidney diseases (29%). Epileptic seizures were the most frequent symptoms at initial clinical presentation. The regions in the brain that were most commonly involved were the occipital region (n = 65, 96%), the parietal region (n = 52, 77%), and the frontal lobe (n = 35, 54%). Magnetic resonance imaging (MRI) findings were consistent with atypical patterns in most of the study cohort (71%). Patients with unfavorable clinical outcomes (n = 13, 19.1%) had longer initial seizure times and longer encephalopathy times, lower leucocyte and absolute neutrophil counts, and lower neutrophil to lymphocyte ratios. No relationship was found between MRI findings, involvement patterns, and neurologic outcomes.Conclusions: No clinically specific differences between two different age groups were found. Atypical imaging manifestations of pediatric PRES in our study had an incidence that was as high as those found in earlier adult studies. Multivariate logistic regression analysis showed that the initial neutrophil to lymphocyte ratio, absolute neutrophil counts, and white cell counts could not predict poor neurologic outcomes.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15562
Pediatric posterior reversible encephalopathy syndrome: Age related clinico‐radiological profile and neurologic outcomes
Background: The aim of this study was to analyze the characteristics of pediatric posterior reversible encephalopathy syndrome (PRES) to determine clinical and radiologic differences between younger and older age groups, and to identify risk factors for development of any neurologic sequelae.Methods: The study cohort consisted of confirmed pediatric PRES patients in a tertiary care university hospital from January, 2015, to December, 2020. Demographic and clinical properties, radiological manifestations, and neurologic outcomes were noted. Children aged ≤6 years were compared with those older than 6 years and factors affecting neurologic outcomes were evaluated.Results: The most common underlying diseases were oncological (37%) and kidney diseases (29%). Epileptic seizures were the most frequent symptoms at initial clinical presentation. The regions in the brain that were most commonly involved were the occipital region (n = 65, 96%), the parietal region (n = 52, 77%), and the frontal lobe (n = 35, 54%). Magnetic resonance imaging (MRI) findings were consistent with atypical patterns in most of the study cohort (71%). Patients with unfavorable clinical outcomes (n = 13, 19.1%) had longer initial seizure times and longer encephalopathy times, lower leucocyte and absolute neutrophil counts, and lower neutrophil to lymphocyte ratios. No relationship was found between MRI findings, involvement patterns, and neurologic outcomes.Conclusions: No clinically specific differences between two different age groups were found. Atypical imaging manifestations of pediatric PRES in our study had an incidence that was as high as those found in earlier adult studies. Multivariate logistic regression analysis showed that the initial neutrophil to lymphocyte ratio, absolute neutrophil counts, and white cell counts could not predict poor neurologic outcomes.
- Open Access
- 28 December 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (4) , 1578-1583
Çocuklarda Wilms tümörü dışındaki böbrek tümörlerinde risk grubunun sağkalıma etkisi
Purpose: The aim of this study was to evaluate tne effect of the risk group on the clinical features of the disease, treatment strategies and especially survival in children with Non-Wilms’ renal tumors (NWRTs). Materials and Methods: Patients diagnosed with NWRTs followed up and treated between January 2012 and January 2022 were included in the study (n=29; 16 boys and 13 girls). They were categorized into high- and low-risk groups based on their histological type. Patient records were reviewed retrospectively. Clinical characteristics, treatments, and outcomes of these patients were analyzed. Results: The high-risk group comprised clear cell sarcoma (CCSK) (n=8, 27.6%), malignant rhabdoid tumor (MRT) (n=3, 10.3%), renal cell carcinoma (n=2, 6.9%), non-Hodgkin lymphoma (n=1, 3.4%), and primitive neuroectodermal tumor (PNET) (n=1, 4%). The low-risk group comprised congenital mesoblastic nephroma (CMN) (n=9, 31%), angiomyolipoma (n=4, 3.8%), and hemangioma (n=1, 3.4%). Five patients died due to disease progression (mortality rate, 17%), all of whom belonged to the high-risk group (three patients with MRT, one with CCSK, one with PNET). The 5-year survival rate was 72% for the high risk group and 100% for the low risk group. Conclusion: Although low-risk tumors are associated with excellent outcomes, the outcomes vary in high-risk tumors. Physicians should be wary of high mortality rates in children with MRT, CCSK, and PNET, and should design multidisciplinary treatments for NWRTs.
- 28 December 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (4) , 1578-1583
Open AccessÇocuklarda Wilms tümörü dışındaki böbrek tümörlerinde risk grubunun sağkalıma etkisi
Purpose: The aim of this study was to evaluate tne effect of the risk group on the clinical features of the disease, treatment strategies and especially survival in children with Non-Wilms’ renal tumors (NWRTs). Materials and Methods: Patients diagnosed with NWRTs followed up and treated between January 2012 and January 2022 were included in the study (n=29; 16 boys and 13 girls). They were categorized into high- and low-risk groups based on their histological type. Patient records were reviewed retrospectively. Clinical characteristics, treatments, and outcomes of these patients were analyzed. Results: The high-risk group comprised clear cell sarcoma (CCSK) (n=8, 27.6%), malignant rhabdoid tumor (MRT) (n=3, 10.3%), renal cell carcinoma (n=2, 6.9%), non-Hodgkin lymphoma (n=1, 3.4%), and primitive neuroectodermal tumor (PNET) (n=1, 4%). The low-risk group comprised congenital mesoblastic nephroma (CMN) (n=9, 31%), angiomyolipoma (n=4, 3.8%), and hemangioma (n=1, 3.4%). Five patients died due to disease progression (mortality rate, 17%), all of whom belonged to the high-risk group (three patients with MRT, one with CCSK, one with PNET). The 5-year survival rate was 72% for the high risk group and 100% for the low risk group. Conclusion: Although low-risk tumors are associated with excellent outcomes, the outcomes vary in high-risk tumors. Physicians should be wary of high mortality rates in children with MRT, CCSK, and PNET, and should design multidisciplinary treatments for NWRTs.